395 related articles for article (PubMed ID: 29984339)
1. Intravesical electrical stimulation treatment for overactive bladder: An observational study.
Yune JJ; Shen JK; Pierce MA; Hardesty JS; Kim J; Siddighi S
Investig Clin Urol; 2018 Jul; 59(4):246-251. PubMed ID: 29984339
[TBL] [Abstract][Full Text] [Related]
2. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle.
Dokmeci F; Cetinkaya SE; Seval MM; Dai O
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584
[TBL] [Abstract][Full Text] [Related]
3. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
4. Flat Magnetic Stimulation for Urge Urinary Incontinence.
Barba M; Cola A; Rezzan G; Costa C; Re I; Volontè S; Terzoni S; Frigerio M; Maruccia S
Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38004048
[No Abstract] [Full Text] [Related]
5. A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints.
Heesakkers JPFA; Digesu GA; van Breda J; Van Kerrebroeck P; Elneil S
Neurourol Urodyn; 2018 Mar; 37(3):1060-1067. PubMed ID: 28892221
[TBL] [Abstract][Full Text] [Related]
6. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
7. The minimum important difference for the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire.
Mamik MM; Rogers RG; Qualls CR; Morrow JD
Int Urogynecol J; 2014 Oct; 25(10):1321-6. PubMed ID: 24562789
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Sacral Neuromodulation in Patients with Prior Surgical Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse.
Bartley JM; Ramirez V; Killinger KA; Boura JA; Gupta P; Gaines N; Gilleran JP; Peters KM
Female Pelvic Med Reconstr Surg; 2017; 23(1):8-12. PubMed ID: 27636222
[TBL] [Abstract][Full Text] [Related]
9. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study.
Peters KM; Carrico DJ; MacDiarmid SA; Wooldridge LS; Khan AU; McCoy CE; Franco N; Bennett JB
Neurourol Urodyn; 2013 Jan; 32(1):24-9. PubMed ID: 22674493
[TBL] [Abstract][Full Text] [Related]
10. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
12. A single-blind, randomized controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in Overactive Bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS).
Martin-Garcia M; Crampton J
Physiotherapy; 2019 Dec; 105(4):469-475. PubMed ID: 30862384
[TBL] [Abstract][Full Text] [Related]
13. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.
Yüce T; Dökmeci F; Çetinkaya ŞE
Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
17. Effect of extracorporeal magnetic energy stimulation on bothersome lower urinary tract symptoms and quality of life in female patients with stress urinary incontinence and overactive bladder.
Lo TS; Tseng LH; Lin YH; Liang CC; Lu CY; Pue LB
J Obstet Gynaecol Res; 2013 Nov; 39(11):1526-32. PubMed ID: 23855601
[TBL] [Abstract][Full Text] [Related]
18. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
[TBL] [Abstract][Full Text] [Related]
19. Association of baseline severity of lower urinary tract symptoms with the success conservative therapy for urinary incontinence in women.
Obloza A; Teo R; Marriott E; Parker G; Tincello D
Int Urogynecol J; 2019 May; 30(5):705-710. PubMed ID: 30306193
[TBL] [Abstract][Full Text] [Related]
20. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
